Loading
A phase 1/2 trial of Adebrelimab, Carboplatin, Cisplatin, Pemetrexed and Cetuximab in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT06385678 by Jiangsu HengRui Medicine Co., Ltd., with 47 participants enrolled, started 2024-07-05 and due to reach its primary completion in 2025-12. Interventions recorded: HRS-4642, Adebrelimab, SHR-9839, Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection and Cetuximab Solution for Infusion.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin and the tag pipeline.
Shares Adebrelimab, Cetuximab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cetuximab, Pemetrexed, Cisplatin, Carboplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Pemetrexed, Carboplatin and the tag pipeline.